ATE120201T1 - Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon. - Google Patents

Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon.

Info

Publication number
ATE120201T1
ATE120201T1 AT90402329T AT90402329T ATE120201T1 AT E120201 T1 ATE120201 T1 AT E120201T1 AT 90402329 T AT90402329 T AT 90402329T AT 90402329 T AT90402329 T AT 90402329T AT E120201 T1 ATE120201 T1 AT E120201T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
tnfs
sens
rns
alpha
Prior art date
Application number
AT90402329T
Other languages
English (en)
Inventor
Abdel Karim Braham
Pierre Smets
Rene Zalisz
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE120201T1 publication Critical patent/ATE120201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K2203/00—Specific aspects not provided for in the other groups of this subclass relating to the windings
    • H02K2203/03—Machines characterised by the wiring boards, i.e. printed circuit boards or similar structures for connecting the winding terminations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Thin Magnetic Films (AREA)
AT90402329T 1989-08-23 1990-08-22 Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon. ATE120201T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8911171A FR2651130B1 (fr) 1989-08-23 1989-08-23 Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.

Publications (1)

Publication Number Publication Date
ATE120201T1 true ATE120201T1 (de) 1995-04-15

Family

ID=9384878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90402329T ATE120201T1 (de) 1989-08-23 1990-08-22 Anti-sens nukleotidsequenz, anti-rns des alpha- tnfs, verfahren zu deren herstellung und deren verwendung als arzneimittel und pharmazeutische präparate davon.

Country Status (19)

Country Link
US (1) US5705389A (de)
EP (1) EP0414607B1 (de)
JP (1) JPH0391485A (de)
KR (1) KR0151153B1 (de)
CN (1) CN1028760C (de)
AT (1) ATE120201T1 (de)
AU (1) AU642423B2 (de)
CA (1) CA2023899C (de)
DE (1) DE69017983T2 (de)
DK (1) DK0414607T3 (de)
ES (1) ES2069715T3 (de)
FR (1) FR2651130B1 (de)
GR (1) GR3015527T3 (de)
HU (1) HU215242B (de)
IE (1) IE68592B1 (de)
IL (1) IL95342A (de)
PT (1) PT95067B (de)
RU (1) RU2066325C1 (de)
ZA (1) ZA906675B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250722B (it) * 1991-07-30 1995-04-21 Univ Degli Studi Milano Oligonucleotidi antisenso
TW323284B (de) * 1992-03-23 1997-12-21 Novartis Ag
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1999027086A1 (en) * 1997-11-25 1999-06-03 Brax Group Limited Chimeric antisense oligonucleotides against tnf-alpha and their uses
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
CN101235064B (zh) * 2008-02-27 2011-08-10 东南大学 可脱保护的硫代核苷酸单体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090789A1 (de) * 1982-03-26 1983-10-05 Monsanto Company Chemische DNA-Synthese
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
FR2584090B1 (fr) 1985-06-27 1987-08-28 Roussel Uclaf Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
WO1990000624A1 (en) * 1988-07-05 1990-01-25 Baylor College Of Medecine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria

Also Published As

Publication number Publication date
FR2651130A1 (fr) 1991-03-01
IL95342A (en) 1995-01-24
AU642423B2 (en) 1993-10-21
ES2069715T3 (es) 1995-05-16
PT95067A (pt) 1991-04-18
KR0151153B1 (ko) 1998-08-17
ZA906675B (en) 1991-10-30
CA2023899C (fr) 2002-05-14
GR3015527T3 (en) 1995-06-30
IE903036A1 (en) 1991-02-27
IL95342A0 (en) 1991-06-30
CN1049668A (zh) 1991-03-06
HU905302D0 (en) 1991-02-28
FR2651130B1 (fr) 1991-12-13
DE69017983T2 (de) 1995-09-28
EP0414607A3 (en) 1991-04-03
AU6119090A (en) 1991-02-28
JPH0391485A (ja) 1991-04-17
CN1028760C (zh) 1995-06-07
DK0414607T3 (da) 1995-06-06
EP0414607A2 (de) 1991-02-27
RU2066325C1 (ru) 1996-09-10
KR910004198A (ko) 1991-03-28
HUT56113A (en) 1991-07-29
US5705389A (en) 1998-01-06
EP0414607B1 (de) 1995-03-22
PT95067B (pt) 1997-05-28
CA2023899A1 (fr) 1991-02-24
HU215242B (hu) 1998-11-30
IE68592B1 (en) 1996-06-26
DE69017983D1 (de) 1995-04-27

Similar Documents

Publication Publication Date Title
DE69017983D1 (de) Anti-sens Nukleotidsequenz, anti-RNS des alpha-TNFS, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel und pharmazeutische Präparate davon.
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
ATE160344T1 (de) Heterozyklische alkylamine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
GR3020098T3 (en) 11-Beta-aryl-4-estrene, method for its production and its use as a medicine
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
DE59601683D1 (de) Sulfamat-derivate von 1,3,5(10)-estratrien-derivaten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
FR2642065B1 (fr) Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ATE58538T1 (de) 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE104300T1 (de) Thieno(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
OA08734A (fr) Dérivés d'hydrazine, procédé d'obtention et compositions pharmaceutiques les contenant.
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ATE104848T1 (de) Trapidil enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
DE3767533D1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.
FR2617403B1 (fr) Procede de preparation de derives des acides nucleiques et procede de preparation d'une composition medicale les contenant
IT8620703A1 (it) Derivati dell'acido 4-fenil 4-osso 2-butenoico, loro procedimento di preparazione e loro impiego come prodotti medicinali
ATE61222T1 (de) Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels.
FR2692899B1 (fr) Nouveaux dérivés peptidiques actifs dans les processus d'adhésion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment.
DE3674250D1 (de) Phenylpyrazinderivate, verfahren zu deren herstellung, pharmazeutische zusammensetzung und verwendung.
DE69102082D1 (de) Ungesättigte Gallsäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate diese enthaltend.
ATE94883T1 (de) Salze von glykosaminoglykanen, verfahren zu ihrer herstellung und diese salze enthaltende pharmazeutische zusammensetzungen.
ATE58540T1 (de) Substituierte 1,8-naphthyridinone, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time